Ana sayfa | MS’in Derinliği  | MS Slide Resource

References

1. Matthews WB. Clinical aspects. In: Matthews WB (ed). McAlpine's Multiple Sclerosis. 2nd ed. Edinburgh:Churchill Livingstone, 1991:43-298.

2. Schumacher GA, Beebe G, Kibler RE, et al. Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965;122:552-568.

3. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13(3):227-231.

4. Poser S. Klinik der Multiplen Sklerose. Nervenheilkunde 1984;3:53-58.

5. Thompson AJ, McDonald WI. Multiple sclerosis and its pathophysiology. In: Asbury AK, McKhann GM, McDonald WI (eds). Diseases of the Nervous System. Philadelphia:WB Saunders Company, 1992:1209-1228.

6. Poser CM. Onset symptoms of multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;58:253-264.

7. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: A geographically based study. 1. Clinical course and disability. Brain 1989;112:133-146.

8. Phadke JG. Clinical aspects of multiple sclerosis in North-East Scotland with particular reference to its course and prognosis. Brain 1990;113:1597-1628.

9. Riise T, Grønning M, Fernández O, et al. Early prognostic factors for disability in multiple sclerosis, a European multicenter study. Acta Neurol Scand 1992;85:212-218.

10. Miller AE. Usual and unusual findings in the course of multiple sclerosis. Multiple Sclerosis, Clinical Issues 1993;1(1):6-8.

11. McDonald WI, Barnes D. The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system. J Neurol Neurosurg Psychiatry 1992;55(9):747-752.

12. Poser S, Wikström J, Bauer HJ. Clinical data and identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system. J Neurol Sci 1979;40:159-168.

13. Fowler TJ. Demyelinating disease of the central nervous system. In: Marsden CD, Fowler TJ (eds). Clinical Neurology. London:Edward Arnold, 1989:344-352.

14. Weinshenker BG. The natural history of MS. Multiple Sclerosis, Clinical Issues 1993;1(1):2-3.

15. Matthews B. Multiple sclerosis: The facts. 3rd ed. Oxford:Oxford University Press, 1993.

16. Kurtzke JF, Beebe GW, Nagler B, et al. Studies on the natural history of multiple sclerosis. V. Long-term survival in young men. Arch Neurol 1970;22:215-225.

17. MacLeod J, Munro J (eds). Clinical examination: a textbook for students and doctors. 7th ed. Edinburgh:Churchill Livingstone, 1986.

18. Sibley WA. Diagnosis and course of Multiple Sclerosis. In: Rao SM (ed). Neurobehavioural Aspects of Multiple Sclerosis. New York:Oxford University Press, 1990:5-14.

19. Swanson JW. Multiple sclerosis: Update in diagnosis and review of prognostic factors. Mayo Clin Proc 1989;64:577-586.

20. Beer S, Rösler KM, Hess CW. Diagnostic value of paraclinical tests in multiple sclerosis: relative sensitivities and specificities for reclassification according to the Poser committee criteria. J Neurol Neurosurg Psychiatry 1995;59:152-159.

21. Wallace CJ, Seland TP, Fong TC. Multiple sclerosis: The impact of MR imaging. Am J Roentgenol 1992;158:849-857.

22. Honig LS, Sheremata WA. Magnetic resonance imaging of spinal cord lesions in multiple sclerosis. J Neurol Neurosurg Psychiatry 1989;52:459-466.

23. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993;43(12):2632-2637.

24. Goodkin DE, Rudick RA, Ross JS. The use of brain magnetic resonance imaging in multiple sclerosis. Arch Neurol 1994;51(5):505-516.

25. Thorpe JW, Miller DH. MRI:Its application and impact. Int MS J 1994;1(1):7-15.

26. Paty DW, Oger JJF, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study of comparison with clinical evaluation, evoked potentials, oligoclonal banding and CT. Neurology 1988;38:180-185.

27. Lee KH, Hashimato S, Hooge JP, et al. Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potential, oligoclonal banding and CT. Neurology 1991;41:657-660.

28. Fazekas F, Offenbacher H, Fuchs S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988;38:1822-1825.

29. Offenbacher H, Fazekas F, Schmidt R, et al. Assessment of MRI criteria for diagnosis of MS. Neurology 1993;43(5):905-909.

30. Compston DAS. Immunological aspects of multiple sclerosis. In: Matthews WB (ed). McAlpine's Multiple Sclerosis. 2nd ed. Edinburgh:Churchill Livingstone, 1991:321-340.

31. Mehta PD. Diagnostic usefulness of cerebrospinal fluid in multiple sclerosis. Crit Rev Clin Lab Sci 1991;28(3):233-251.

32. Hallpike J. Multiple sclerosis - making the diagnosis. Aust Fam Physician 1992;21(10):1407-1410.

33. Felgenhauer K, Reiber H. The diagnostic significance of antibody specific indices in multiple sclerosis and herpes virus induced diseases of the nervous system. Clin Investig 1992;70:28-37.

34. McLean BN, Luxton RW, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the log IgG index. Brain 1990;113:1269-1289.

35. Andersson M, Alvarez-Cermeño J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994;57:897-902.

36. Rudick RA, Schiffer RB, Schwetz KM, Herndon RM. Multiple sclerosis. The problem of incorrect diagnosis. Arch Neurol 1986;43(6):578-583.

37. Herndon RM. The changing pattern of misdiagnosis in multiple sclerosis. In: Herndon RM, Seil FJ (eds). Multiple Sclerosis: Current Status of Research and Treatment. New York:Demos, 1994:149-155.

38. Herndon RM, Brooks B. Misdiagnosis of multiple sclerosis. Seminars in Neurology 1985;5(2):94-98.

39. Paty DW, McFarlin DE, McDonald WI. Magnetic resonance imaging and laboratory aids in the diagnosis of multiple sclerosis. Ann Neurol 1991;29:3-5.

40. Poser S, Lüer W, Bruhn H, et al. Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 1992;86:579-585.

41. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.

42. Paty DW, Li DKB, The UBC MS/MRI Study Group, The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.

43. Elian M, Dean G. To tell or not to tell the diagnosis of multiple sclerosis. Lancet 1985;2:27-28.

44. Robinson I. The context and consequences of communicating the diagnosis of multiple sclerosis. In: Wietholder H, Dichgans J, Mertin J (eds). Current Concepts in Multiple Sclerosis. Amsterdam:Elsevier, 1991:17-22.

45. Mushlin AI, Mooney C, Grow V, Phelps CE. The value of diagnostic information to patients with suspected multiple sclerosis. Arch Neurol 1994;51(1):67-72.

46. Benz C. Coping with multiple sclerosis. London:Optima, 1993.

47. Rotteveel FTM, Kuenan B, Kokkelink A, et al. Relative increase of inflammatory CD4+ T cells in the cerebrospinal fluid of multiple sclerosis patients and control individuals. Clin Exp Immunol 1990;79:15-20.

48. Dore-Duffy P, Newman W, Balabanov R. et al. Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical etkinligini. Ann Neurol 1995;37:55-62.

49. Rieckmann P, Martin S, Weichselbraun et al. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis. Neurology 1994;44:2367-2372.

50. Rieckmann P, Albrecht M, Kitze B, et al. Tumor Necrosis Factor-a messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease etkinligini. Ann Neurol 1995;37:82-88.

51. Harris JO, Frank JA, Patronas N, et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991;29:548-555.

52. Sipe JC, Knobler RL, Braheny SL, et al. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984;34:1368-1372.

53. Paty DW, Koopmans RA, Zhao G, et al. Magnetic resonance imaging (MRI) as an outcome measure in multiple sclerosis. J Neuro Rehab 1993;7:117-129.

54. Richards TL. proton MR spectroscopy in multiple sclerosis: Value in establishing diagnosis, monitoring progression, and evaluating therapy. Am J Roentgenol 1991;157:1073-1078.

55. Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease etkinligini in multiple sclerosis. Brain 1993;116:1077-1094.

56. Miller DH. Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol 1994;36:S91-S94.

57. Miller DH, Barkhof F, Berry I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action Guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688.

58. McFarland HF, Frand JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease etkinligini in multiple sclerosis. Ann Neurol 1992;32:758-766.

59. International Federation of Multiple Sclerosis Societies. Symposium on Minimal Record of Disability for Multiple Sclerosis. Acta Neurol Scand 1984;(Suppl 101).

60. Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. Neurology 1956;5:580-583.

61. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.

62. Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: A critique. Neurology 1988;38:1793-1798.

63. Filippi M, Horsfield MA, Morrissey SP, et al. Quantatitive brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44:635-641.

64. Paty DW, Li DKB, Oger JJ-F, et al. Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis. Ann Neurol 1994;36:S95-S96.

65. Kesselring J, Ormerod IEC, Miller DH, et al. Magnetic resonance imaging in multiple sclerosis. An atlas of diagnosis and differential diagnosis. Stuttgart:Georg Thieme Verlag, 1989.

66. Kermode AG, Thompson AJ, Tofts PS, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990;113:1477-1489.

67. Barkhof F, Thompson AJ, Kappos L, et al. Database for serial magnetic resonance imaging in multiple sclerosis. Neuroradiology 1993;35(5):362-366.

68. Paty DW. Magnetic resonance in multiple sclerosis. Curr Opin Neurol Neurosurg 1993;6(2):202-208.

69. Mechtler LL, Kinkel PR. Magnetic resonance imaging in demyelinating, infectious, metabolic, and congenital diseases. Curr Opin Neurol 1993;6(6):912-918.

Bu sayfadaki bilginin en son güncellendiği/doğrulandığı tarih:

11/09/2001

Ana sayfa | Bağlantılar | Kayıt ve geri bildirim | Sözlükçe | Arama motoru ve site haritası | Yerel Bilgiler | Yardım| Bir arkadaşa söyleyin | Sorumluluk almama | Basın Bilgileri | Schering